×
About 928 results

ALLMedicine™ Complex Partial Seizures Center

Research & Reviews  172 results

Carbamazepine Toxicity
https://emedicine.medscape.com/article/813654-overview

Oct 15th, 2021 - Practice Essentials Carbamazepine is an antiepileptic drug widely used for treatment of simple partial seizures and complex partial seizures, trigeminal neuralgia, and bipolar affective disorder. Carbamazepine is also used as a treatment for posth...

Carbamazepine Toxicity
https://emedicine.medscape.com/article/1011240-overview

Oct 15th, 2021 - Practice Essentials Carbamazepine is an antiepileptic drug widely used for treatment of simple partial seizures and complex partial seizures, trigeminal neuralgia, and bipolar affective disorder. Carbamazepine is also used as a treatment for posth...

OV329, a novel highly potent γ-aminobutyric acid aminotransferase inactivator, induces ...
https://doi.org/10.1111/epi.17090
Epilepsia Feja M, Meller S et. al.

Oct 8th, 2021 - An attractive target to interfere with epileptic brain hyperexcitability is the enhancement of γ-aminobutyric acidergic (GABAergic) inhibition by inactivation of the GABA-metabolizing enzyme GABA aminotransferase (GABA-AT). GABA-AT inactivators we...

Complex Partial Seizures Clinical Presentation
http://emedicine.medscape.com/article/1183962-clinical

Jul 26th, 2021 - History The predominant symptoms occurring during a seizure event determine the seizure type. These can be assessed from direct observation or from video recordings (see the video below), but this is relatively rare because most patients with epil...

Complex Partial Seizures
http://emedicine.medscape.com/article/1183962-overview

Jul 26th, 2021 - Practice Essentials A complex partial seizure, now known as a focal impaired awareness seizure according to the updated classification system from the International League Against Epilepsy (ILAE), [1] starts focally within the brain and causes imp...

see more →

Drugs  171 results see all →

Clinicaltrials.gov  5 results

Sabril for Complex Partial Seizures in Adult Tolerability Study (TS) Patients
https://clinicaltrials.gov/ct2/show/NCT01266291

Jul 12th, 2017 - This is an open-label, phase 4 study to examine the safety and efficacy of vigabatrin (Sabril) in Tuberous Sclerosis patients, a subset of the larger refractory complex partial epilepsy population for which the drug is approved. While enrolled on ...

Serotonin Receptors in Seizure Disorders
https://clinicaltrials.gov/ct2/show/NCT00001932

Jul 2nd, 2017 - Objective: to study serotonin receptors in patients with localization-related epilepsy. Studies in experimental animals have suggested that: Serotonin is an anticonvulsant neurotransmitter in a number of seizure models; its anticonvulsant action i...

Sabril Patient Registry
https://clinicaltrials.gov/ct2/show/NCT01073579

Jul 29th, 2016 - This prospective registry is part of the overall Risk Evaluation and Mitigation Strategy (REMS) required for Sabril by the United States Food and Drug Administration (FDA). All physicians who prescribe Sabril and all patients who take Sabril will ...

A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)
https://clinicaltrials.gov/ct2/show/NCT01278173

Jun 7th, 2016 - Multicenter, prospective open-label study with approximately 25 sites in the US that specialize in caring for adult patients with refractory CPS Sites must have access to Humphrey static perimetry and to Spectralis SD-OCT. All vision test results ...

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy
https://clinicaltrials.gov/ct2/show/NCT01140867

Sep 12th, 2011 - The object of this study is to assess the efficacy and safety of zonisamide as adjunctive therapy in patients with uncontrolled partial epilepsy. Subject takes zonisamide for 16 weeks (4 weeks-titration period, 8 weeks maintenance period). Dose ra...

see more →

News  22 results

FDA Clears First Generic Version of Seizure Drug Sabril (Vigabatrin)
https://www.medscape.com/viewarticle/907809

Jan 16th, 2019 - The US Food and Drug Administration (FDA) has approved the first generic version of the antiseizure medication Sabril (vigabatrin, Lundbeck). Generic vigabatrin (500-mg tablets), made by Teva Pharmaceuticals USA, is indicated as add-on therapy for...

Cenobamate Reduces the Frequency of Partial-Onset Seizures
https://www.mdedge.com/neurology/epilepsyresourcecenter/article/169570/epilepsy-seizures/cenobamate-reduces

Jul 5th, 2018 - LOS ANGELES—Adjunctive treatment with an investigational antiepileptic drug (AED) reduces the median frequency of partial-onset seizures, according to trial results presented at the 70th Annual Meeting of the American Academy of Neurology. “The re.

Drug Deposited Directly Into the Brain Effective in Severe Epilepsy
https://www.medscape.com/viewarticle/889978

Dec 12th, 2017 - WASHINGTON, DC — A microinfusion device that continuously delivers valproate directly to the brain is safe and effective in patients with refractory focal epilepsy, early research shows. Delivery of valproate through the intracerebroventricular de...

Epilepsy: Osmosis Study Video
https://www.medscape.com/viewarticle/881523

Jul 21st, 2017 - What is Epilepsy? Epilepsy is a condition characterized by recurrent and unpredictable seizures. Seizures are characterized by groups of neurons being activated simultaneously, leading to both outward symptoms like muscle jerking and convulsions, ...

Old Epilepsy Classification System Updated
https://www.medpagetoday.com/neurology/seizures/63770

Mar 10th, 2017 - Updates to a 1980s classification system of epilepsies and seizure types, which identify several types of seizure not captured in the previous version, are expected to allow more fully informed decisions regarding epilepsy diagnosis, treatment, an...

see more →

Patient Education  1 results see all →